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Background: It is unclear whether dipeptidylpeptidase-4 (DPP-4) inhibition can counteract the impairment of
cognitive function and brain injury caused by transient cerebral ischemia in type 2 diabetes. The present study was
undertaken to test our hypothesis that linagliptin, a DPP-4 inhibitor, administration following transient cerebral
ischemia can ameliorate cognitive impairment and brain injury in diabetic mice.
Methods: db/db mice, a model of obese type 2 diabetes, were subjected to transient cerebral ischemia by 17 min
of bilateral common carotid artery occlusion (BCCAO), and were administered (1) vehicle or (2) linagliptin for
8 weeks or 1 week. For the long-term experiment on 8 weeks of linagliptin treatment, cognitive function, and
volume and neuronal cell number of hippocampus and cortex were estimated in each group of mice. For the short-
term experiment on 1 week of linagliptin treatment, cerebral IgG extravasation, Iba-1 positive cell number (reactive
microglia), oxidative stress, and claudin-5 and gp91phox protein levels were measured in each group of mice.
Results: Linagliptin administration almost completely suppressed the circulating DPP-4 activity in db/db mice, but did
not significantly reduce blood glucose or ameliorate glucose intolerance in db/db mice. Linagliptin administration
following transient cerebral ischemia significantly counteracted cognitive impairment in diabetic mice, as
estimated by water maze test and passive avoidance test. Linagliptin administration ameliorated the decrease in
cerebral volume and neuronal cell number in hippocampus and cortex of diabetic mice. Linagliptin administration
significantly reduced the increase in cerebral IgG extravasation and the increase in reactive microglia caused
by transient cerebral ischemia in diabetic mice. Furthermore, linagliptin significantly suppressed the increase
in cerebral oxidative stress in transient cerebral ischemia-subjected diabetic mice. Furthermore, linagliptin
significantly increased cerebral claudin-5 and significantly decreased gp91phox in diabetic mice subjected to
transient cerebral ischemia.
Conclusions: DPP-4 inhibition with linagliptin counteracted cognitive impairment and brain atrophy induced by
transient cerebral ischemia in diabetic mice, independently of blood glucose lowering effect. This cerebroprotective
effect of linagliptin was associated with the suppression of blood-brain barrier disruption and the attenuation of
cerebral oxidative stress. Thus, our present work highlights DPP-4 inhibition as a promising therapeutic strategy for
cognitive impairment and cerebral vascular complications in type 2 diabetes.
Keywords: Cerebral ischemia, Cognitive function, Brain atrophy, Oxidative stress, blood-brain barrier* Correspondence: mitsuyam@gpo.kumamoto-u.ac.jp
Department of Pharmacology and Molecular Therapeutics, Kumamoto
University Graduate School of Medical Sciences, 1-1-1 Honjo, Kumamoto
860-8556, Japan
© 2015 Ma et al. This is an Open Access articl
License (http://creativecommons.org/licenses/
any medium, provided the original work is pr
(http://creativecommons.org/publicdomain/zeroe distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in
operly credited. The Creative Commons Public Domain Dedication waiver
/1.0/) applies to the data made available in this article, unless otherwise stated.
Ma et al. Cardiovascular Diabetology  (2015) 14:54 Page 2 of 13Introduction
Type 2 diabetes is one of the major risk factors contrib-
uting to stroke, ischemic heart disease, or heart failure
[1, 2], and is known to be associated with the increased
risk of cognitive decline such as Alzheimer’s disease and
vascular dementia [3–5]. However, there has been con-
troversy regarding whether strict glycemic control can
reduce macrovascular disease in type 2 diabetic patients.
Furthermore, it remains to be determined whether gly-
cemic control can prevent the onset or progression of
cognitive impairment in diabetic patients.
Dipeptidylpeptidase 4 (DPP-4) inhibitors are a new class
of blood glucose-lowering drug and used for treatment of
type 2 diabetes [6–9]. DPP-4 inhibitors have low risk of
hypoglycemia and neutral effect on body weight and take
the advantage of less adverse events than other conven-
tional anti-diabetic agents. DPP-4 inhibitors, through the
inhibition of degradation of incretin hormone, glucagon-
like peptide-1 (GLP-1), prolong the physiologic effect of
GLP-1, thereby enhancing physiologically regulated insu-
lin secretion. DPP-4 inhibitors are thought to participate
in the regulation of other peptides than GLP-1, since
DPP-4 is a multifunctional enzyme and cleaves a number
of other substrates than GLP-1, such as the sister incretin
gastric inhibitory polypeptide (GIP), neuropeptide, cy-
tokines, and chemokines [6–9]. Thus, DPP-4 inhibitors
are proposed to potentially exert pleiotropic effects in-
dependently of blood glucose lowering effect. Previous
preclinical studies show that DPP-4 inhibitors counter-
act stroke in the normal and diabetic mouse brain [10],
ameliorate cognitive impairment in streptozotosin-
induced diabetic rat [11], high-fat fed mice [12], and a
mouse model of chronic cerebral hypoperfusion [13],
lessen the development of cerebral infarction induced
by temporally focal ischemia in non-diabetic normal
mice [14], improve cognition in high-fat diet induced
insulin resistant rats [15], and delay some forms of Alz-
heimer’s disease pathology in Alzheimer’s prone mice
[16]. However, it remains to be defined whether DPP-4
inhibitor administration following short transient cere-
bral ischemia can counteract cognitive impairment and
brain injury in type 2 diabetes. In the present study, we
hypothesized that DPP-4 inhibition, partially independ-
ently of blood glucose control, might ameliorate cogni-
tive impairment and brain atrophy induced by transient
cerebral ischemia in diabetic mice and if so, examined
the potential role of blood-brain barrier disruption and
oxidative stress. To test our hypothesis, we used db/db
mice, since db/db mice is recognized as one of the most
popular animal models of type 2 diabetes with obesity
[17, 18], and also used linagliptin for specific DPP-4 in-
hibition, because linagliptin is shown to exert brain
protective effect in mice independently of blood glu-
cose control [10].Methods
Animals
All procedures were carried out according to the
Kumamoto University Committee for Laboratory Animal
Care and use. All of the experimental procedures were
performed in accordance with guidelines on animal sci-
ence. Male db/db mice and nondiabetic C57BL/6 J mice
were purchased from Japan Charles River Laboratories
Japan Inc. (Yokohama, Japan). All animals were housed in
an animal facility with a 12-hour light–dark cycle and
were given the standard chow and water ad libitum.
Drugs
Linagliptin was kindly provided by Boehringer Ingelheim.
Experiment I protocol
The detail of Experimental I protocol is shown in Fig. 1.
Eight-week-old male db/db mice were subjected to 17 min
of transient global cerebral ischemia, as described below.
Following transient global cerebral ischemia, db/db mice
were randomly assigned 2 groups, and were given (1) the
standard diet (MF diet, ORIENTAL YEAST Co., Ltd,
Tokyo, Japan) or (2) the standard diet containing linaglip-
tin (0.083 g/kg diet), for 8 weeks. This dose of linagliptin
(0.083 g/kg diet) was established to sufficiently inhibit the
circulating DPP-4 activity [19, 20]. In our preliminary
experiments, we measured diet intake of db/db mice and
found that oral intake of linagliptin in our present study
was roughly 10 mg/kg/day. This dose of linagliptin is
regarded as an appropriate dose because 3–10 mg/kg/day
of linagliptin by oral administration is most often used to
examine the effect of linagliptin in vivo [10, 21, 22].
Sham-operated db/db mice were served as the control.
Non-fasting blood sugar was periodically measured
throughout the experiment. At specified time points,
cerebral blood flow, passive avoidance test, water maze
test, oral glucose tolerance test, and blood pressure
measurement were performed according to the method
described below (see Fig. 1). At the end of the treatment
(8 weeks after BCCAO), the animals were anesthetized
with 3 % isoflurane and then sacrificed for histological
examination. The brain was removed quickly and cut
from bregma. An 8 μm-slice was made from the level of
bregma −1.43 mm to bregma −2.43 mm for the following
histological evaluations including volume of hippocampus
and cortex, neuronal cell number.
Experiment II protocol
The protocol of the Experiment II was the same as that
of Experiment I, except for the difference in duration of
linagliptin administration. db/db mice were subjected to
BCCAO for 17 min and then were given (1) the stand-
ard diet (MF diet, ORIENTAL YEAST Co., Ltd, Tokyo,















Fig. 1 Experimental design. Abbreviations used: BCCAO, bilateral common carotid arterial occlusion; BS, blood sugar measurement; CBF,
measurement of cerebral blood flow; OGTT, oral glucose tolerance test; BP, measurement of blood pressure
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(7 days) linagliptin administration on cerebral IgG ex-
travasation, cerebral activated microglia, and oxidative
stress was examined.
Transient global cerebral ischemia model
db/db mice were anesthetized with 3 % isoflurane and
maintained with 2 % isoflurane via a facemask. The rec-
tal temperature was controlled at 37.0 ± 0.5 °C during
surgery with a feedback-regulated heating pad. Transient
global ischemia was induced by bilateral common carotid
artery occlusion (BCCAO). Briefly, BCCA were isolated
and occluded with a microvascular clip. After 17 min,
the clips were removed to allow reperfusion. The mice
were kept in a single cage and allowed free access to
food and water.
Measurement of cerebral blood flow
Cerebral blood flow was measured using a laser speckle
blood flow imager (Omega Zone; Omegawave, Tokyo,
Japan) as previously described [23]. The blood flow at
the times of pre-operation, post-operation, reperfusion
and sacrifice were measured. The value of blood flow was
expressed as a percentage of the pre-operation.
Passive avoidance test
The passive avoidance test was performed as two sec-
tions including (1) training section and (2) memory test
section. On the training section, we performed the test
as two steps. In Step 1, we put the db/db mice into the
white side of the test box and let the mice be free move-
ment for 60 s. In Step 2, 30 min after the step one, put
the mice into the white side of the test box and recorded
the second until the mice went into the dark place (4 paws
into the dark side). After the door was closed, the mice
were given the electric shock (1.6 mA, 3 s) and kept in the
dark side of the test box for 60 s. Repeat the step two until
the mouse did not go into the dark side for 300 s. On thememory test section, we put the mice into the white side
of the test box one day and three days after the training
section, then recorded the seconds when the mouse went
into the dark place (upper limit for 300 s).
Morris water maze tests
The Morris water maze was performed as previously
described [24]. The test was included four sessions: 1)
training session, 2) hidden platform session, 3) visible
platform test. After the training session, hidden platform
test was performed five sessions per day on the following
four days (day 1 to 4). On the visible platform test the
platform was cued and the mice were released from dif-
ferent points.
Measurement of blood pressure
The blood pressure was measured in the conscious mice
at 6 weeks after BCCAO, using the tail cuff method (BP-
98A; Softron Co, Tokyo, Japan).
Oral glucose tolerance test (OGTT)
The oral glucose tolerance test was performed as previ-
ously described [25]. Briefly, mice were fasted for over-
night and then orally given glucose (1 mg/g body weight).
Tail vein bloods were taken and the serum glucose con-
centrations were measured at 0, 30, 60 and 120 min after
glucose administration using a portable glucose meter
(Sanwa Kagaku Kenkyusho CO., LTD, Nagoya, Japan).
The evaluation of brain atrophy and surviving neurons
For the assessment of volume of hippocampus and cortex,
the slices were selected every 200 μm from bregma −1.43
to bregma −2.43 and stained with Nissl staining. Areas of
the bilateral hippocampus and cortex on each slice were
calculated separately and added together and multiplied
by slice thickness to give the volume. For the assessment
of surviving pyramidal cells and the neurons in cortex, the
selected area of hippocampus (1 field in each side of CA1
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counted in each side at × 200 magnification) were counted
using Lumina Vision version 2.2.0 analysis software and
the average number of surviving pyramidal cells and
neurons in cortex were used for evaluation of the neur-
onal injury.
The measurement of activated microglia
For the assessment of number of activated microglia,
brain sections were immunostained with anti-ionized cal-
cium binding adaptor molecule-1. (Iba-1(ab5076); 1:500;
Abcam, Tokyo, Japan) as previously described [26]. The
number of positive cells was counted in both the CA1 re-
gion of hippocampus (1 field was counted in each side of
CA1 region at × 200 magnification) and the cortex (2 fields
were counted in each side at × 200 magnification). The
number of cells was expressed as cells/mm2.
Measurement of immunoglobulin G extravasation
Brain immunolocalization of immunoglobulin G was mea-
sured as previously described [27, 28]. IgG immunoreac-
tivity was quantified in both sides the CA1 region of
hippocampus (1 field was counted in each side of CA1 re-
gion at × 200 magnification) and the cortex (2 fields were
counted in each side of cortex at × 200 magnification).
The value was measured with Lumina Vision version 2.2.0
analysis software (Mitani Corporation, Tokyo, Japan) and
expressed as the mean value compared with the sham-
operated group.
Detection of superoxide
To detect superoxide levels in hippocampus and cortex,
dihydroethidium (DHE; SIgam, St. Louis, MO, USA) stain-
ing was used in situ as previously described [29]. The fro-
zen tissue sections were stained with DHE fluorescence
and measured using Lumina Vision version 2.2.0 analysis
software. The mean fluorescence was quantified in both
sides the CA1 region of hippocampus (1 field was counted
in each side of CA1 region at × 200 magnification) and
the cortex (2 fields were counted in each side of cortex
at × 200 magnification). Each value was expressed re-
lated to individual group sham-operated mouse. The
results were expressed relative to values obtained for
sham-operated mouse.
Western blotting
The detailed Western blot method has been previously
described [30]. Briefly, the front part of brain protein
extracts were subjected to sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and transferred to
polyvinylidene difluoride membranes. The antibodies
used were as follows: anti-claudin-5 (ab53765) (1:500;
Abcam), GAPDH (sc-32233) (1:5000; Santa Cruz Bio-
technology, Santa Cruz, CA, USA), anti-gp91phox (sc-20782) (1:1000; Santa Cruz Biotechnology, Santa Cruz,
CA, USA). The membranes were incubated for 1 h with
appropriate secondary antibodies and processed with an
enhanced chemiluminescence reagent kit (Amersham
ECL plus kit, GE Healthcare, UK). Mouse or rabbit sec-
ondary antibody (1:5000 or 1:30000; Cell Signaling) was
used in accordance with first antibody. The antibodies
were visualized by using an enhanced chemilumines-
cence method (ECL Plus; GE Healthcare, Buckingham-
shire, UK). The intensity of the bands was quantified by
using analysis software (Image J; National Institute of
Health, Bethesda, MD, USA). In individual samples,
each value was corrected for that of GAPDH.
Measurement of DPP-4 activity and GLP-1 in serum and
brain tissue and serum insulin
DPP-4 activity, GLP-1 concentrations, and serum insulin
were determined in samples from mice subjected to
8 weeks of linagliptin treatment. Serum and brain DPP-4
activities were measured using DPP4-Glo Protease Assay
(Promega, Madison, WI, USA), as described [21]. Active
GLP-1 concentrations in serum and brain tissue were
measured by the Active form Assay Kit-IBL (Immuno-
Biological Laboratories, Gunma, Japan). Serum insulin
concentrations were measured by Morinaga ultra sensi-
tive mouse insulin ELISA kit.
Statistical analysis
Data were presented as mean ± SEM. The data on time
course experiments were analyzed by two-way ANOVA
with repeated measures followed by Bonferroni post hoc
test for multiple comparisons. Statistical significance was
determined with one-way ANOVA, followed by the Tukey's
multiple comparisons test between each group. When a
normal distribution was not confirmed among compari-
son groups, data were analyzed by Dunn’s multiple com-
parison test. Data were analyzed by non-paired t-test
when two groups were compared. All analyses were per-
formed using GraphPad Prism 6.0 for Mac (GraphPad
Software, Inc; La Jolla, CA, USA). In all tests, differ-
ences were considered statistically significant at a value
of P < 0.05.
Results
Effect of transient BCCAO on non-diabetic versus diabetic
mice
In our preliminary experiment, we compared the effect
of transient global cerebral ischemia (17 min of BCCAO)
between non-diabetic and diabetic mice. As shown in
Fig. 2a-d, 17 min of BCCAO did not significantly impair
cognitive function and visual acuity, and did not affect brain
weight or cerebral blood flow in non-diabetic mice, com-
pared with sham operation. In contrast to non-diabetic




















































































































































Fig. 2 Effect of transient cerebral ischemia on cognitive function and brain injury in non-diabetic mice versus diabetic mice. Cognitive function
was estimated by Morris water maze test. a, b, c, and d indicate escape latency of the hidden platform test on 4 consecutive days (1–20 sessions),
escape latency in the visible test, brain weight, and cerebral blood flow, respectively, in non-diabetic mice. Each value represents mean ± SEM
(n = 6 in Sham, n = 5 in BCCAO). e, f, g, and h indicate escape latency of the hidden platform test on 4 consecutive days (1–20 sessions), escape
latency in the visible test, brain weight, and cerebral blood flow, respectively, in diabetic mice. Each value represents mean ± SEM (n = 6 in Sham, n = 5
in BCCAO). Abbreviations used: Sham, sham-operated group; BCCAO, group subjected to bilateral common carotid arterial occlusion
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bral blood flow in diabetic db/db mice (Fig. 2e-h).
Effect of linagliptin on body weight, blood sugar, glucose
tolerance, insulin concentrations, DPP-4 activity, GLP-1
concentrations, and blood pressure of db/db mice
subjected to transient BCCAO
Eight weeks of linagliptin administration (Fig. 3a) did
not significantly alter body weight in db/db mice sub-
jected to transient BCCAO. There was no significant
difference in blood sugar throughout the treatment
between linagliptin and vehicle groups of db/db mice
subjected to transient BCCAO (Fig. 3b). Furthermore, as
shown by OGTT and blood sugar area under curve
(AUC) during OGTT in Fig. 3c and d, linagliptin did not
significantly improve glucose tolerance in db/db mice
subjected to transient BCCAO. However, blood sugar AUC
in linagliptin group was significantly smaller than that in
sham group (P < 0.01). Serum insulin concentrations insham group, vehicle group subjected to BCCAO, and
linagliptin group subjected to BCCAO were 1.62 ± 0.51,
1.16 ± 0.29, and 1.08 ± 0.21 ng/ml, respectively, and
there was no significant difference in serum insulin con-
centrations among the groups.
As shown in Fig. 3e, serum DPP-4 activity in
linagliptin-treated group subjected to BCCAO was much
less than that in vehicle-treated group subjected to BCCAO
(P < 0.01) or sham-operated group (P < 0.01). Serum GLP-1
concentrations in linagliptin-treated group were signifi-
cantly larger than those in vehicle group or sham group
(Fig. 3f). As shown in Fig. 3g and h, linagliptin treatment
significantly decreased brain DPP-4 activity (P < 0.01) and
significantly increased brain GLP-1 concentrations (P <
0.05) in db/db mice subjected to BCCAO compared with
vehicle treatment.
Blood pressure was 129 ± 4 mmHg in sham group,
110 ± 3 mmHg in vehicle group subjected to transient











































































































































































Fig. 3 Effect of long-term linagliptin administration on body weight (a), blood sugar (b), oral glucose tolerance test (c), blood sugar area under
curve (AUC) during OGTT (d), serum DPP-4 activity (e), serum GLP-1 (f), brain DPP-4 activity (g), and brain GLP-1 (h) in db/db mice subjected
to transient BCCAO. OGTT in (c) and (d) were performed after 6 weeks of linagliptin administration. In (e), the mean value of sham group was
expressed as 100 %. Abbreviations used: Sham, sham-operated group; BCCAO + Veh, group subjected to transient BCCAO followed by vehicle
administration; BCCAO + Lin, group subjected to transient BCCAO followed by linagliptin administration; AUC, area under curve; NS, not significant
between groups. Each value represents mean ± SEM. In (a)-(d), n = 10 in Sham, n = 10 in BCCAO + Veh, n = 11 in BCCAO + Lin. In (e) and (f), n = 9
in Sham, n = 5 in BCCAO + Veh, n = 7 in BCCAO + Lin. In (g) and (h), n = 10 in Sham, n = 9 in BCCAO + Veh, n = 11 in BCCAO + Lin
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ence in blood pressure between vehicle and linagliptin
groups of db/db mice.
Effect of linagliptin on cognitive function of db/db mice
subjected to transient BCCAO
As shown by Fig. 4a, transient BCCAO of db/db mice
significantly increased escape latency of the hidden plat-
form test on water maze test (P < 0.01) compared with
sham operation. Linagliptin administration significantly
suppressed the increase in escape latency of the hidden
platform test in db/db mice subjected to BCCAO (P <
0.01). In Fig. 4b, there was no significant difference in
visual acuity between the groups. As shown in Fig. 4c,
transient BCCAO in db/db mice significantly decreased
latency on day 3 of passive avoidance test compared with
sham operation (P < 0.01) and this decrease in latency of
db/db mice subjected to BCCAO was significantly sup-
pressed by linagliptin (P < 0.01).Effect of linagliptin on cerebral blood flow and brain
weight of db/db mice subjected to transient BCCAO
As shown in Fig. 5, being in consistent with our prelimin-
ary experiment (Fig. 2), transient BCCAO in db/db mice
significantly decreased cerebral blood flow (P < 0.05) and
brain weight (P < 0.01) compared with sham operation.
Linagliptin administration significantly suppressed the
decrease in cerebral blood flow (P < 0.05) and the de-
crease in brain weight (P < 0.01) of db/db mice sub-
jected to BCCAO.Effect of linagliptin on volume and neuronal cell number
of hippocampus and cortex of db/db mice subjected to
transient BCCAO
As shown in Fig. 6, transient BCCAO in db/db mice
significantly reduced volume of hippocampus (P < 0.01)
and volume of cortex (P < 0.01) compared with sham
































































Fig. 4 Effect of long-term linagliptin administration on escape latency of the hidden platform test (a), escape latency in the visible test (b), latency
of the passive avoidance test (C) in db/db mice subjected to transient BCCAO. Abbreviations used are the same as in Fig. 4. Each value represents
mean ± SEM (n = 10 in Sham, n = 10 in BCCAO + Veh, n = 11 in BCCAO + Lin)
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ume of cortex (P < 0.05) of BCCAO-subjected db/db
mice.
As shown in Fig. 7, transient BCCAO in db/db
























Fig. 5 Effect of long-term linagliptin administration on cerebral blood flow
Abbreviations used are the same as in Fig. 4. Each value represents mean ±
Upper panels in (a) and (b) indicate representative cerebral blood flow imahippocampal CA1 region (P < 0.01) and in cortex (P <
0.01). Linagliptin administration significantly prevented
the reduction of neuronal cell number in hippocampal






















(a) and brain weight (b) in db/db mice subjected to transient BCCAO.
SEM (n = 10 in Sham, n = 10 in BCCAO + Veh, n = 11 in BCCAO + Lin).



















































Fig. 6 Effect of long-term linagliptin administration on volume of hippocampus and cortex in db/db mice subjected to transient BCCAO. a
indicates representative image of Nissle-stained cerebral coronal section of each group. Bar = 2 mm. b and c indicate volume of hippocampus
and cortex, respectively of each group. Abbreviations used are the same as in Fig. 4. Each value represents mean ± SEM (n = 10 in Sham, n = 10 in
BCCAO + Veh, n = 11 in BCCAO + Lin)
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brain barrier, reactive microglia, and cerebral oxidative
stress of db/db mice subjected to transient BCCAO
As shown in Fig. 8a and b, transient BCCAO in db/db
mice significantly increased IgG extravasation in the brain
compared with sham operation (P < 0.01) and this increase
in IgG extravasation was significantly ameliorated by lina-
gliptin (P < 0.01). As shown in Fig. 8c, linagliptin adminis-
tration to BCCAO-subjected db/db mice significantly
increased cerebral claudin-5 (P < 0.01).
As shown in Fig. 9, transient BCCAO significantly in-
creased Iba-1 positive cell number in cortex (P < 0.01) and
in hippocampus (P < 0.01) of db/db mice, and the increase
in Iba-1positive cell number induced by BCCAO was sig-
nificantly suppressed by linagliptin administration.
DHE staining of cerebral sections in Fig. 10a-c showed
that oxidative stress in cortex and hippocampus was
greater in BCCAO-subjected db/db mice than in sham
group of db/db mice. Linagliptin administration to
BCCAO-subjected db/db mice significantly reducedoxidative stress in cerebral cortex (P < 0.05) and in hippo-
campus (P < 0.05). As shown in Fig. 10d, linagliptin admin-
istration to BCCAO-subjected db/db mice significantly
decreased cerebral gp91phox (P < 0.05).
Discussion
The purpose of the present study was to test our hy-
pothesis that DPP-4 inhibition with linagliptin following
short transient cerebral ischemia can counteract cognitive
impairment and brain atrophy in obese type 2 diabetes.
The major findings of this study were that linagliptin ad-
ministration counteracted the impairment of cognitive
function and brain atrophy induced by short transient
cerebral ischemia in type 2 diabetic mice and this cerebro-
protective effect of linagliptin was associated with the
suppression of blood-brain barrier disruption and the at-
tenuation of oxidative stress in the brain of diabetic mice.
The duration of cerebral ischemia by BCCAO used in
this study was short time (for 17 min) and did not sig-





























































Fig. 7 Effect of long-term linagliptin administration on number of neuronal cells in hippocampal CA1 region (a) and cortex (b) in db/db mice
subjected to transient BCCAO. Upper panels in (a) and (b) indicate representative photomicrographs of hippocampus and cortex, respectively,
of each group. Bar = 100 μm. Abbreviations used are the same as in Fig. 4. Each value represents mean ± SEM ((a): n = 10 in Sham, n = 10 in

















































Fig. 8 Effect of 7 days of linagliptin administration on IgG extravasation and cerebral claudin-5 in the brain of db/db mice subjected to transient
BCCAO. a indicates representative image of IgG immunostained cerebral section of each group and (b) indicates relative density of IgG staining.
Bar = 2 mm. (c) indicates relative density of cerebral claudin-5 estimated by western blot. Upper panels in (c) indicate representative western blot
band. In individual mouse, claudin-5 wes corrected for GAPDH. Abbreviations used are the same as in Fig. 3. Each value represents mean ± SEM
(n = 7 in Sham, n = 6 in BCCAO + Veh, n = 7 in BCCAO + Lin.)

































































Fig. 9 Effect of 7 days of linagliptin administration on Iba-1 positive cell number in cortex and hippocampus of db/db mice subjected to transient
BCCAO. a indicates representative photomicrograph of Iba-1 immunostained cerebral sections. Bar = 100 μm. b and c indicate Iba-1 positive cell
number in cortex and hippocampus, respectively. Abbreviations used are the same as in Fig. 4. Each value represents mean ± SEM (n = 7 in Sham,
n = 6 in BCCAO + Veh, n = 7 in BCCAO + Lin.)
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estingly, in contrast to non-diabetic mice, such a short
transient cerebral ischemia significantly impaired cogni-
tive function and caused brain atrophy in diabetic mice.
Therefore, it is possible that hyperglycemia might en-
hance the vulnerability to ischemic brain injury. How-
ever, the potential role of obesity and hyperlipidemia in
ischemic brain injury cannot be excluded, since db/db
mice exhibit not only hyperglycemia but also obesity and
hyperlipidemia [18, 31]. Of note, linagliptin administra-
tion following transient cerebral ischemia in diabetic
mice significantly decreased escape latency of the hidden
platform test on water maze test and significantly in-
creased latency on passive avoidance test, providing the
evidence that linagliptin ameliorated cognitive dysfunc-
tion induced by transient cerebral ischemia in diabetic
mice. Furthermore, linagliptin administration signifi-
cantly ameliorated the decrease in cerebral blood flow
and the decrease in brain weight, and these effects of
linagliptin were associated with the suppression of the
decrease in volume of hippocampus and cortex and
with the inhibition of decrease in hippocampal and cor-
tical neuronal cell number. These results demonstrate
that linagliptin suppressed cerebral ischemia-induced
brain atrophy in diabetic mice, through the inhibition
of neuronal cell death.blood-brain barrier plays a key role in the pathophysi-
ology of brain function, stroke, and dementia [32–35].
The disruption of blood-brain barrier causes the enhance-
ment of cerebral oxidative stress and inflammation. Fur-
thermore, oxidative stress and inflammation form vicious
cycle and accelerates brain injury and cognitive impair-
ment. To address the potential mechanism underlying the
above mentioned brain protective effects of linagliptin, we
examined the effects of linagliptin administration on
blood-brain barrier function, activation of microglia, and
oxidative stress in transient cerebral ischemia-induced dia-
betic mice. Linagliptin administration significantly amelio-
rated the disruption of blood-brain barrier and the
activation of microglia, as shown by the reduction of
cerebral IgG extravasation and by the reduction of Iba-1
positive cell number by linagliptin in diabetic mice sub-
jected to cerebral ischemia. Furthermore, linagliptin sig-
nificantly attenuated cerebral oxidative stress induced
by cerebral ischemia in diabetic mice, as shown by the
significant attenuation of superoxide in hippocampal
and cortical tissues by linagliptin. To address the under-
lying molecular mechanism, we examined the effect of
linagliptin on cerebral claudin-5 and gp91phox levels in
cerebral ischemia-subjected diabetic mice, since
claudin-5 [36, 37] is a main cerebral endothelial tight
















































































Fig. 10 Effect of 7 days of linagliptin administration on oxidative stress in cortex and hippocampus, and cerebral gp91phox of db/db mice subjected
to transient BCCAO. a indicates representative photomicrograph of DHE-stained cerebral sections. Bar = 100 μm. b and c indicate relative DHE
fluorescence in cortex and hippocampus, respectively. d indicates cerebral gp91phox levels corrected to GAPDH. In d, upper panels indicate
representative western blot band. Abbreviations used are the same as in Fig. 3. Each value represents mean ± SEM (n = 7 in Sham, n = 6 in
BCCAO + Veh, n = 7 in BCCAO + Lin.)
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NADPH oxidase, the main oxidative stress-generating
enzyme. We found that linagliptin significantly increased
cerebral claudin-5 and decreased the increase in gp91phox
in diabetic mice. Hence, the prevention of blood-brain
barrier disruption and the attenuation of cerebral oxida-
tive stress by linagliptin seem to be partially mediated by
the increase in claudin-5 and the decrease in gp91phox,
respectively. However, further study is needed to define
the detailed molecular mechanism responsible for brain
protective effects of linagliptin in transient cerebral
ischemia-subjected diabetic mice.
It is a very critical issue as to whether the cerebropro-
tective effects of linagliptin observed in this study was
attributed to glucose lowering effect or not. In the present
study, linagliptin treatment almost completely suppressed
serum DPP-4 activity and significantly increased serum
GLP-1 levels in db/db mice. Moreover, linagliptin treat-
ment significantly decreased brain DPP-4 activity and in-
creased brain GLP-1 concentrations in db/db mice. These
results confirm that the dose of linagliptin (0.083 g/kg
diet) used in this study was pharmacologically enough
dose. However, sufficient suppression of DPP-4 activity
led to only small improvement of glucose tolerance in db/
db mice. Our present findings are in good agreement withthe previous reports showing that marked DPP-4 inhib-
ition failed to reduce blood glucose or improve glucose
tolerance in db/db mice with similar ages to our present
work [22, 38, 39]. In contrast to no significant improve-
ment of glucose tolerance by DPP-4 inhibition in db/db
mice at the late stage of severe diabetes [22, 38, 39],
linagliptin is reported to significantly reduce blood glu-
cose and improve glucose tolerance in younger db/db
mice at the early stage of diabetes [40]. Collectively, our
present findings showing only slight improvement of
glucose tolerance with sufficient DPP-4 inhibition can
be explained by the use of older db/db mice with severe
insulin resistance and diabetes. Despite slight improve-
ment of glucose tolerance, DPP-4 inhibition with lina-
gliptin significantly protected against brain injury in db/
db mice subjected to BCCAO. Furthermore, GLP-1 re-
ceptor activation is shown to exert neuroprotection and
protect against cognitive impairment in mice [41]. Col-
lectively, our preset work provided the notion that lina-
gliptin exerts brain protective effects partially via blood
glucose-independent mechanism. However, it cannot be
ruled out that brain protective effects of linagliptin
might be partially mediated by blood glucose control,
since linagliptin slightly but significantly improved glu-
cose tolerance in db/db mice.
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There are several study limitations in our present work.
First, in the present study, cerebral claudin-5 levels did
not differ between sham and vehicle groups, thereby not
excluding the possibility that clauding-5 might play a
minor role in blood-brain barrier disruption induced by
BCCAO. Further study is necessary for the precise mech-
anism of blood-brain barrier disruption in this study. Sec-
ond, in the present study, we did not measure GIP levels
in db/db mice, because the pathophysiological role of GIP
elevation by DPP-4 inhibition is poorly understood.
Therefore, further study investigating the potential role
of GIP is needed to define the precise mechanism
underlying brain protective effect of linagliptin. Third,
the mechanism underlying brain protection by linagliptin
was examined at 1 week after BCCAO, since the signifi-
cant disruption of blood-brain barrier and the enhance-
ment of cerebral oxidative stress occurred at 1 week after
BCCAO. However, the study at additional time point
might be necessary for further determination of the under-
lying mechanism. Fourth, in the present study, we did not
perform power calculation for determination of number of
animals in each experimental group. However, we per-
formed appropriate statistical analysis, thereby validating
our present results. Finally, the present study did not allow
us to elucidate which dose of linagliptin is appropriate to
protect against stroke or cognitive impairment in clinical
practice. Future randomized clinical study is required to
elucidate this point.
In conclusion, our present work provided the evidence
that DPP-4 inhibition with linagliptin following transient
cerebral ischemia ameliorates blood-brain barrier break-
down and oxidative stress, and thereby counteracts the
impairment of cognitive function and brain atrophy due
to the reduction of hippocampal and cortical neuronal
cell in type 2 diabetic mice. Furthermore, this cerebropro-
tective effect of linagliptin seems to be at least partially
mediated by blood glucose-independent effect. Therefore,
we propose that DPP-4 inhibition may be a promising
strategy for prevention and treatment of ischemic brain
injury and cognitive decline in type 2 diabetes. However,
future randomized clinical study is warranted to elucidate
our proposal.
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